A Phase I Open Label Dose Escalation Trial of RNA-144101 in the Treatment of Geographic Atrophy

Summary

This is a non-randomized, open-label, dose-escalating Phase Ia study performed at a single center designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of intravitreous administration of RNA-144101 in patients with geographic atrophy (GA).

Timeline

Start

2011-03

Primary completion

2012-09

Completion

2012-09

Outcome

Outcome not reported

Stopped (Enrollment): “Study was not conducted, no subjects recruited.”

Drugs

Indications